ライフサイエンスコーパス: neoadjuvant chemotherapy

1 to define the extent of breast cancer before neoadjuvant chemotherapy.

2 and included consecutive patients treated by neoadjuvant chemotherapy.

3 e in baseline characteristics was the use of neoadjuvant chemotherapy.

4 s of breast-conserving surgery and pCR after neoadjuvant chemotherapy.

5 cluded patients, 400 patients (68%) received neoadjuvant chemotherapy.

6 tients suffering from PRMS were treated with neoadjuvant chemotherapy.

7 or single anti-HER2 treatment in addition to neoadjuvant chemotherapy.

8 administration with anthracycline and taxane neoadjuvant chemotherapy.

9 ns of BRCA score with genome instability and neoadjuvant chemotherapy.

10 ry before and those undergoing surgery after neoadjuvant chemotherapy.

11 derwent surgery first and 652 (22%) received neoadjuvant chemotherapy.

12 patients undergoing surgery before or after neoadjuvant chemotherapy.

13 -FDG PET for early prediction of response to neoadjuvant chemotherapy.

14 with either upfront surgery or surgery after neoadjuvant chemotherapy.

15 gulated in residual tumor cells that survive neoadjuvant chemotherapy.

16 asurements were acquired before the start of neoadjuvant chemotherapy.

17 tted in selected women with good response to neoadjuvant chemotherapy.

18 f pathologic response in subjects undergoing neoadjuvant chemotherapy.

19 educed E-cadherin expression in tumors after neoadjuvant chemotherapy.

20 ndividual patients with breast cancer before neoadjuvant chemotherapy.

21 c survival outcomes in patients treated with neoadjuvant chemotherapy.

22 this stage for the selection of patients for neoadjuvant chemotherapy.

23 r to develop and test genomic predictors for neoadjuvant chemotherapy.

24 e AJCC staging system for patients receiving neoadjuvant chemotherapy.

25 abetic patients with breast cancer receiving neoadjuvant chemotherapy.

26 ed to assess the likelihood of efficacy from neoadjuvant chemotherapy.

27 operative evaluation of sentinel nodes after neoadjuvant chemotherapy.

28 ermining prognosis for patients treated with neoadjuvant chemotherapy.

29 resection, 43 of whom were embolized during neoadjuvant chemotherapy.

30 None of these patients received neoadjuvant chemotherapy.

31 negative tumors resected from patients after neoadjuvant chemotherapy.

32 went (18)F-FDG PET/CT scans before and after neoadjuvant chemotherapy.

33 deciding between surgical cytoreduction and neoadjuvant chemotherapy.

34 hemotherapy have shown a beneficial role for neoadjuvant chemotherapy.

35 response of breast cancer after one cycle of neoadjuvant chemotherapy.

36 dicting residual pathologic tumor size after neoadjuvant chemotherapy.

37 regional lymph nodes in women who underwent neoadjuvant chemotherapy.

38 d provides information regarding response to neoadjuvant chemotherapy.

39 first (n = 21) and second (n = 15) cycle of neoadjuvant chemotherapy.

40 ESFTs correlates with histologic response to neoadjuvant chemotherapy.

41 entinel node concept is applicable following neoadjuvant chemotherapy.

42 loc 2-field lymphadenectomy in patients post neoadjuvant chemotherapy.

43 elp predict the response of breast cancer to neoadjuvant chemotherapy.

44 disease (POST-TEXT) stages III and IV after neoadjuvant chemotherapy.

45 outcomes in a node-positive cohort receiving neoadjuvant chemotherapy.

46 he Ki67 was > 10%, patients were switched to neoadjuvant chemotherapy.

47 asets on breast cancer patients who received neoadjuvant chemotherapy.

48 deally to no visible disease) should receive neoadjuvant chemotherapy.

49 surgery and axillary dissection (ALND) after neoadjuvant chemotherapy.

50 surgery reduces the FNR of SLN surgery after neoadjuvant chemotherapy.

51 performed at baseline and after 2 cycles of neoadjuvant chemotherapy.

52 complete response (pCR) is not reached after neoadjuvant chemotherapy.

53 or tripe negative breast cancer resistant to neoadjuvant chemotherapy.

54 hemotherapy was known, 27,300 (23%) received neoadjuvant chemotherapy.

55 assessment of the pathologic response after neoadjuvant chemotherapy.

56 ith node-positive breast cancer treated with neoadjuvant chemotherapy.

57 d complete response or partial response with neoadjuvant chemotherapy.

58 lative survival benefit with the addition of neoadjuvant chemotherapy (1507 patients, HR 0.88, 95% CI

59 ake at baseline on PET/CT and response after neoadjuvant chemotherapy according to criteria from the

60 rwent surgery before and those who underwent neoadjuvant chemotherapy after surgery.

61 ients were randomized to receive adjuvant or neoadjuvant chemotherapy alone (control group) or chemot

62 am with a minimisation technique, to receive neoadjuvant chemotherapy alone or with 1 year of trastuz

63 2-negative disease was included and received neoadjuvant chemotherapy alone.

64 nts with rectal cancer who were treated with neoadjuvant chemotherapy also received postoperative sys

65 pression is associated with poor response to neoadjuvant chemotherapy and an increased risk of relaps

66 Radiological response rates after neoadjuvant chemotherapy and chemoradiotherapy were 74%

67 ith 1 year of trastuzumab (concurrently with neoadjuvant chemotherapy and continued after surgery).

68 ly changes in blood flow (BF) in response to neoadjuvant chemotherapy and evaluated with (15)O-water

69 c invasive breast cancer who did not receive neoadjuvant chemotherapy and factors associated with a l

70 stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are

71 test cohort (TC) of 62 patients treated with neoadjuvant chemotherapy and interval debulking surgery.

72 n was strongly associated with resistance to neoadjuvant chemotherapy and poor clinical outcomes.

73 15 mg/kg, every 3 weeks for six cycles) with neoadjuvant chemotherapy and postoperatively for ten dos

74 with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed

75 idelines recommend that patients who receive neoadjuvant chemotherapy and radiation for locally advan

76 n prostate cancer specimens before and after neoadjuvant chemotherapy and radical prostatectomy.

77 hat SLN biopsy is applicable before or after neoadjuvant chemotherapy and remapping is feasible inpat

78 ith clinical stages II to III rectal cancer, neoadjuvant chemotherapy and selective radiation does no

79 In this study, we compared response to neoadjuvant chemotherapy and survival between patients w

80 of true T4a stage requires consideration of neoadjuvant chemotherapy and the need for extended pelvi

81 ith pathologic complete response (pCR) after neoadjuvant chemotherapy and to explore the association

82 outcome as early as after the first cycle of neoadjuvant chemotherapy and was more accurate than clin

83 Preoperative (neoadjuvant) chemotherapy and radiotherapy are more effe

84 ucibility and ability to monitor response to neoadjuvant chemotherapy, and determine surgical resecta

85 n other methods of assessing the response to neoadjuvant chemotherapy, and is helpful in identifying

86 ional lymphatic spread could be targeted for neoadjuvant chemotherapy, and patients with distant meta

87 of 2 protocols using doxorubicin-containing neoadjuvant chemotherapy, and who had assessment by phys

88 with three different types of commonly used neoadjuvant chemotherapies: anthracycline alone, anthrac

89 hologic response and lymph node status after neoadjuvant chemotherapy are prognostic in patients trea

90 We included 1,118 patients who received neoadjuvant chemotherapy at M.D. Anderson Cancer Center

91 internal cohort of 804 patients treated with neoadjuvant chemotherapy at our institution from 2003 to

92 ng 2,302 breast cancer patients treated with neoadjuvant chemotherapy at The University of Texas M.D.

93 on patients with breast cancer treated with neoadjuvant chemotherapy at The University of Texas MD A

94 positive breast cancer patients treated with neoadjuvant chemotherapy, BCSS and OS were associated wi

95 Neoadjuvant chemotherapy before cystectomy confers a sur

96 or patients with gastric cancer treated with neoadjuvant chemotherapy before surgery for the accurate

97 Neoadjuvant chemotherapy before surgery improves surviva

98 Ten patients completed neoadjuvant chemotherapy before surgery.

99 tly treated with surgery, while 28 underwent neoadjuvant chemotherapy beforehand.

100 Patients who are downstaged by neoadjuvant chemotherapy benefit from reduced rates of l

101 Patients receiving neoadjuvant chemotherapy between 1997 and 2005 were iden

102 ncers who underwent breast MR imaging before neoadjuvant chemotherapy between April 10, 2008, and Mar

103 s, MYC signaling did not predict response to neoadjuvant chemotherapy but was associated with poor pr

104 Early metabolic change during neoadjuvant chemotherapy can predict pathologic response

105 and 3 patients with untreated breast cancer (neoadjuvant chemotherapy candidates, tumor size > 2 cm)

106 Main advances are with neoadjuvant chemotherapy, chemoradiation, and preventive

107 MD Anderson taxane plus anthracycline-based neoadjuvant chemotherapy cohort (MD Anderson-NeoACT; n=5

108 ve-ACT; n=697), the Nottingham anthracycline neoadjuvant chemotherapy cohort (Nottingham-NeoACT; n=20

109 Neoadjuvant chemotherapy comprising cisplatin, doxorubic

110 ed with residual pathologic tumor size after neoadjuvant chemotherapy (correlation coefficients: 0.42

111 ermining prognosis for patients treated with neoadjuvant chemotherapy could be facilitated.

112 of biopsy-proven node-positive patients with neoadjuvant chemotherapy could safely permit sentinel ly

113 Patients received three cycles of neoadjuvant chemotherapy (CT; modified mesna, doxorubici

114 r results suggest that the reduction after 2 neoadjuvant chemotherapy cycles of the metabolically act

115 After 2 neoadjuvant chemotherapy cycles, the reduction of each p

116 sophagogastric junction adenocarcinoma after neoadjuvant chemotherapy determines prognosis rather tha

117 The intrinsic subtype model predicted neoadjuvant chemotherapy efficacy with a negative predic

118 ment consisted of a multimodal protocol with neoadjuvant chemotherapy, enucleation, orbital external-

119 wait of 30 +/- 2 days after PVE, patients on neoadjuvant chemotherapy experienced a median contralate

120 tients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI

121 Patients with downstaged tumors after neoadjuvant chemotherapy experienced improved survival c

122 ly 8-20% of breast cancer patients receiving neoadjuvant chemotherapy fail to achieve a measurable re

123 For resectable lesions, studies on neoadjuvant chemotherapy failed to convincingly demonstr

124 nd clinically relevant survival benefit, and neoadjuvant chemotherapy followed by definitive local th

125 atment with a uniform protocol consisting of neoadjuvant chemotherapy followed by enucleation, adjuva

126 All patients received neoadjuvant chemotherapy followed by enucleation, radiot

127 Neoadjuvant chemotherapy followed by hepatic resection i

128 primary treatment: either primary surgery or neoadjuvant chemotherapy followed by interval surgery.

129 cancer at the time of diagnosis treated with neoadjuvant chemotherapy followed by locoregional therap

130 He received four cycles of cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy

131 The patient was advised to undergo neoadjuvant chemotherapy followed by radical cystectomy

132 rrent standard of care for these patients is neoadjuvant chemotherapy followed by radical cystoprosta

133 al for patients with gastric carcinoma after neoadjuvant chemotherapy followed by surgery.

134 nd 298, respectively), a cohort who received neoadjuvant chemotherapy followed by tamoxifen and/or ar

135 al junction adenocarcinoma who have received neoadjuvant chemotherapy followed by transthoracic esoph

136 and PET scans before and after completion of neoadjuvant chemotherapy, followed by surgery.

137 acyclines and taxanes have been the standard neoadjuvant chemotherapies for breast cancer in the past

138 ve the potential to help predict response to neoadjuvant chemotherapy for breast cancer as early as c

139 carboplatin (PTX/CBP) regimen, an effective neoadjuvant chemotherapy for breast cancer patients.

140 Neoadjuvant chemotherapy for breast cancer provides crit

141 anthracyclines could improve pCR in standard neoadjuvant chemotherapy for breast cancer.

142 Cs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer.

143 mental regimens in combination with standard neoadjuvant chemotherapy for breast cancer.

144 to first-line therapy, 31 patients received neoadjuvant chemotherapy for localized/locally advanced

145 To assess the role of neoadjuvant chemotherapy for locally advanced squamous h

146 ositron emission tomography (PET) scan after neoadjuvant chemotherapy for resectable non-small-cell l

147 To evaluate the risk of neoadjuvant chemotherapy for surgical morbidity after ma

148 ating long-term survival with four cycles of neoadjuvant chemotherapy for surgically resectable SCUC.

149 rospective database of patients treated with neoadjuvant chemotherapy from 1997 to 2003 was reviewed,

150 T0-4N1-2 breast cancer patients treated with neoadjuvant chemotherapy from 2009 to 2011.

151 her increasing the duration and intensity of neoadjuvant chemotherapy further improved survival compa

152 Patients receiving neoadjuvant chemotherapy had more advanced disease at ba

153 mors that demonstrated a good response after neoadjuvant chemotherapy had significantly lower (18)F-F

154 The use of neoadjuvant chemotherapy has become more prevalent in th

155 Neoadjuvant chemotherapy has been explored in an attempt

156 the rate of breast-conserving surgery after neoadjuvant chemotherapy has not been well studied.

157 r survival, such as pathological response to neoadjuvant chemotherapy, has the potential to improve t

158 s with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do

159 trates that breast cancer patients receiving neoadjuvant chemotherapy have no increased risk for surg

160 However, patients with RD after neoadjuvant chemotherapy have significantly worse surviv

161 adjusted for baseline staging, smoking, and neoadjuvant chemotherapy (hazard ratio, 2.03; 95% CI, 1.

162 Therapy for colon cancer (FOxTROT) trial of neoadjuvant chemotherapy in advanced resectable colon ca

163 eases (P = .001) in mean Hb(T) levels during neoadjuvant chemotherapy in breast abnormality ROIs for

164 predicts better response to PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who

165 rvival and pathological complete response to neoadjuvant chemotherapy in breast cancer patients.

166 tumor response prediction after 2 cycles of neoadjuvant chemotherapy in breast cancer.

167 iated with pathological complete response to neoadjuvant chemotherapy in ER-negative disease, suggest

168 and safety of adding bevacizumab to standard neoadjuvant chemotherapy in HER2-negative early breast c

169 re on outcomes and pathologic findings after neoadjuvant chemotherapy in IRSS stage III retinoblastom

170 the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases.

171 urtosis appears to be associated with pCR to neoadjuvant chemotherapy in non-triple-negative breast c

172 To measure residual disease after neoadjuvant chemotherapy in order to improve the prognos

173 Chemotherapy, and neoadjuvant chemotherapy in particular, was given more f

174 assessing sentinel lymph node surgery after neoadjuvant chemotherapy in patients presenting with nod

175 During neoadjuvant chemotherapy in patients with breast cancer,

176 overall survival (OS) after response-guided neoadjuvant chemotherapy in patients with early breast c

177 es), and the safety of adding bevacizumab to neoadjuvant chemotherapy in patients with early-stage br

178 whether GGI predicts pathologic response to neoadjuvant chemotherapy in patients with HER-2-normal b

179 n in the primary tumour predicts response to neoadjuvant chemotherapy in the liver metastases, and in

180 Our data merit further research into neoadjuvant chemotherapy in the setting of CRS and HIPEC

181 ecular and clinical considerations for using neoadjuvant chemotherapy in the treatment of locally adv

182 ature was associated with better response to neoadjuvant chemotherapy in TNBC (P < 0.0001) but not in

183 and a predictive marker for the response to neoadjuvant chemotherapy in TNBC, implying a potential r

184 with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-p

185 gnosis rather than the clinical stage before neoadjuvant chemotherapy, indicating the importance of f

186 Response to neoadjuvant chemotherapy is a significant prognostic fac

187 Neoadjuvant chemotherapy is among variables identified a

188 Neoadjuvant chemotherapy is an accepted part of the mana

189 Neoadjuvant chemotherapy is associated with lower overal

190 Neoadjuvant chemotherapy is being used with increasing f

191 tion of residual pathologic tumor size after neoadjuvant chemotherapy is critical in guiding surgical

192 Before neoadjuvant chemotherapy is delivered, all patients shou

193 Neoadjuvant chemotherapy is established in the managemen

194 Neoadjuvant chemotherapy is given more frequently to bla

195 clinical interest of axillary staging after neoadjuvant chemotherapy is increasing and this approach

196 rience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited.

197 ome sequencing of samples obtained following neoadjuvant chemotherapy is representative of the genomi

198 rcinomas, and although it responds poorly to neoadjuvant chemotherapy, it appears to respond well to

199 al after receiving taxane plus anthracycline neoadjuvant chemotherapy (MD Anderson-NeoACT: HR 0.68, 9

200 Tumor perfusion changes over the course of neoadjuvant chemotherapy measured directly by [(15)O]wat

201 atory analysis suggests that response-guided neoadjuvant chemotherapy might improve survival and is m

202 nd analyzed for outcome (n=536), response to neoadjuvant chemotherapy (n=125) and platinum resistance

203 rly changes in (18)F-FDG tumor uptake during neoadjuvant chemotherapy (NAC) can predict outcomes.

204 The increasing use of neoadjuvant chemotherapy (NAC) for operable breast cance

205 Treatment with neoadjuvant chemotherapy (NAC) has made it possible for

206 for sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in cN1 disease.

207 Neoadjuvant chemotherapy (NAC) induces a pathological co

208 t of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) recipients in California.

209 -FDG PET/CT performed at baseline and during neoadjuvant chemotherapy (NAC) was able to early depict

210 e response (pCR) of primary breast cancer to neoadjuvant chemotherapy (NAC).

211 axillary pathologic complete response after neoadjuvant chemotherapy (NAC).

212 strates a pathologic tumor response (pTR) to neoadjuvant chemotherapy (NAC).

213 onse (pCR) in women undergoing breast cancer neoadjuvant chemotherapy (NAC).

214 DG PET/CT imaging for pathologic response to neoadjuvant chemotherapy (NACT) and outcome in inflammat

215 dvanced ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) compared with primary cy

216 ts of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epith

217 In neoadjuvant chemotherapy (NACT) pathological complete re

218 ologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT).

219 ctors of locoregional recurrence (LRR) after neoadjuvant chemotherapy (NC) has resulted in controvers

220 Neoadjuvant chemotherapy (NC) is increasingly being used

221 ough most breast cancer patients who receive neoadjuvant chemotherapy (NCT) have a tumor response, a

222 y if percutaneous biopsy of the breast after neoadjuvant chemotherapy (NCT) indicates pCR in the brea

223 finding of a pathologic complete response to neoadjuvant chemotherapy (no evidence of residual invasi

224 treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure

225 Neoadjuvant chemotherapy often yields a partial response

226 staging system for assessing prognosis after neoadjuvant chemotherapy on the basis of pretreatment cl

227 Selecting patients for neoadjuvant chemotherapy on the basis of risk of node-po

228 horoid and optic nerve, decision in favor of neoadjuvant chemotherapy on the basis of suspected postl

229 equired to make definitive conclusions about neoadjuvant chemotherapy, onset of PMs, and mucinous his

230 ially resectable disease, may receive either neoadjuvant chemotherapy or primary cytoreductive surger

231 y on the right lobe of the liver (OR = 1.6), neoadjuvant chemotherapy (OR = 2), and a transverse subc

232 of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and regist

233 95% CI, 91-95) and 90% (95% CI, 87-93) after neoadjuvant chemotherapy (P < 0.001)].

234 The patient had multiple concerns regarding neoadjuvant chemotherapy, particularly toxicities, espec

235 monitor therapeutic response in stage II/III neoadjuvant chemotherapy patients.

236 between metabolic response after 2 cycles of neoadjuvant chemotherapy, pCR, and outcome in patients r

237 at baseline (PET/CT-1) and after 3 cycles of neoadjuvant chemotherapy (PET/CT-2).

238 and distant progression after 2-4 cycles of neoadjuvant chemotherapy plus RHT for STS.

239 d adaptive randomization to compare standard neoadjuvant chemotherapy plus the tyrosine kinase inhibi

240 t of disease at presentation and response to neoadjuvant chemotherapy predict the risk of locoregiona

241 Neoadjuvant chemotherapy prevented orbital exenterations

242 urvival was strongly dictated by stage after neoadjuvant chemotherapy, rather than clinical stage at

243 Neoadjuvant chemotherapy reduces the need for axillary l

244 and 1 week into a 3-month adriamycin/cytoxan neoadjuvant chemotherapy regimen can predict final, post

245 I or II breast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential o

246 ing neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve out

247 Although neoadjuvant chemotherapy remains the preferred approach

248 ed the role of (18)F-FDG PET/CT for staging, neoadjuvant chemotherapy response evaluation, and final

249 n women with breast cancer who are receiving neoadjuvant chemotherapy show a mean decrease in Hb(T) w

250 en section analysis in patients treated with neoadjuvant chemotherapy showed acceptable sensitivity,

251 The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rat

252 The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rat

253 for resistance and response to preoperative (neoadjuvant) chemotherapy (stratified according to ER st

254 ression was reduced among women who received neoadjuvant chemotherapy, suggesting a role for chemothe

255 10% or less residual viable tumour after neoadjuvant chemotherapy, termed here major pathological

256 mor regression score in NSCLC patients under neoadjuvant chemotherapy than algorithms and methods usi

257 tratifies patients with respect to LRR after neoadjuvant chemotherapy than presenting clinical stage

258 This review summarizes the current data on neoadjuvant chemotherapy, the rationale for this approac

259 spite level I evidence supporting the use of neoadjuvant chemotherapy, there remains disagreement reg

260 as not been validated for patients receiving neoadjuvant chemotherapy; thus, prognosis is determined

261 In patients treated with neoadjuvant chemotherapy, TLS density was similar, but G

262 esection should be considered for PVE during neoadjuvant chemotherapy to improve subsequent recovery

263 The use of neoadjuvant chemotherapy to improve the likelihood of re

264 recently, the possibility has opened up for neoadjuvant chemotherapy to provide information on the u

265 Patients were treated with neoadjuvant chemotherapy, transthoracic esophagectomy, a

266 Molecular analysis of the tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic canc

267 ptical imaging method on the first day after neoadjuvant chemotherapy treatment can discriminate nonr

268 mor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary bre

269 Such patients are excluded from neoadjuvant chemotherapy trials and pooled with patients

270 of this study was to determine variations in neoadjuvant chemotherapy use in a large multi-center nat

271 quisition to monitor breast tumor DeltaBF to neoadjuvant chemotherapy using (18)F-FDG PET/CT.

272 mor pathology) for assessing prognosis after neoadjuvant chemotherapy using pretreatment clinical sta

273 Neoadjuvant chemotherapy was able to avoid exenteration

274 Neoadjuvant chemotherapy was associated with decreased o

275 line staging, age, comorbidity, smoking, and neoadjuvant chemotherapy was higher (hazard ratio, 3.39;

276 Primary, preoperative, or neoadjuvant chemotherapy was introduced in the early 197

277 Use of neoadjuvant chemotherapy was not significant when added

278 patients with resectable NSCLC treated with neoadjuvant chemotherapy, we found no evidence that tumo

279 data on both types of scan before and after neoadjuvant chemotherapy were analyzed regarding SUVmax,

280 y and tumor in the optic nerve cut end after neoadjuvant chemotherapy were associated with inferior o

281 who underwent liver resection for CRLM after neoadjuvant chemotherapy were evaluated.

282 Patients receiving neoadjuvant chemotherapy were excluded from this analysi

283 nd their variation (Delta) after 2 cycles of neoadjuvant chemotherapy were extracted from the PET ima

284 , 28-82 years; mean age, 49 years) receiving neoadjuvant chemotherapy were monitored with 3.0-T MR im

285 negative breast cancer and an indication for neoadjuvant chemotherapy were prospectively included.

286 Patients who were eligible for neoadjuvant chemotherapy were recruited between December

287 cT4aN0M0) received a total of four cycles of neoadjuvant chemotherapy, whereas those with unresectabl

288 Among women with cN1 breast cancer receiving neoadjuvant chemotherapy who had 2 or more SLNs examined

289 assess the safety and long-term efficacy of neoadjuvant chemotherapy with capecitabine and oxaliplat

290 e addition of capecitabine or gemcitabine to neoadjuvant chemotherapy with docetaxel, followed by dox

291 She received neoadjuvant chemotherapy with doxorubicin plus cyclophos

292 tion (LVEF) >/= 55% at study entry following neoadjuvant chemotherapy with or without radiotherapy.

293 Neoadjuvant chemotherapy with or without second-look sur

294 This phase II trial evaluated the effect of neoadjuvant chemotherapy with or without second-look sur

295 )F-FDG PET/CT before and after 2-4 cycles of neoadjuvant chemotherapy with RHT for STS.

296 We performed a phase II study of neoadjuvant chemotherapy with the objective of determini

297 Neoadjuvant chemotherapy with trastuzumab for patients w

298 or extensive residual disease (n = 11) after neoadjuvant chemotherapy, with cases from The Cancer Gen

299 ched propensity analysis was performed using neoadjuvant chemotherapy within 30 days of surgery as tr

300 ollowed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women